

CASE STUDY:

Minimally Invasive Case Study

Sudden Blood Loss during Exploratory Laparotomy

INTRODUCTION

New minimally invasive monitoring tools can be extremely valuable when guiding fluid resuscitation in cases with anticipated or sudden unexpected blood loss. Arterial pressure-based cardiac output (APCO) monitoring and central venous oximetry enable clinicians to manage patients' oxygen delivery more precisely than traditional vital signs alone. Stroke Volume Variation (SVV), a parameter available with APCO monitoring, has been shown to be a sensitive indicator of a patient's preload responsiveness.


Clinical Events


Patient Details: 72-year-old female, 5'2", 72.7 kg
Medical History: Previous medical history revealed hypertension

CASE NOTES

The patient experienced a sudden 2-liter blood loss due to intraoperative complications during the removal of a large peri-vaginal mass. Minimally invasive monitoring was initiated with a left radial arterial line and arterial pressure-based cardiac output (APCO) sensor (Edwards FloTrac sensor, Edwards Lifesciences, Irvine, CA, USA) along with a right internal central venous oximetry catheter (Edwards PreSep catheter, Edwards Lifesciences, Irvine, CA, USA) and monitored using a dedicated monitor (Edwards Vigileo monitor, Edwards Lifesciences, Irvine, CA, USA). Stroke Volume Variation (SVV) was used to monitor the patient's preload responsiveness and guide blood and saline resuscitation. Normal saline and blood were infused rapidly through the PreSep catheter to achieve SVV values of less than 13% during duration of the

patient's surgery. Total volume replacement included 6 units of packed red blood cells and 4 liters of normal saline.






SVV Increased to 19%

DISCUSSION

The application of this less-invasive, easy-to-use hemodynamic monitoring device allowed the clinician to appropriately manage fluid resuscitation in the face of large and ongoing blood loss. SVV was used to establish the patient's preload responsiveness and guide fluid resuscitation throughout the surgical procedure preventing over or under resuscitation. One aberrant SVV value of 25% was noted at 2:32 secondary to an arrhythmia. Cardiac output was optimized as the primary component of DO₂ and the adequacy of delivery was confirmed with ScvO₂.

Submitted by:

John Frazier RN, RRT
 Clinical Marketing
 Edwards Lifesciences
 Irvine, California USA



SVV Decreased to 9 -8% after volume

Rx only. See instructions for use for full prescribing information.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, FloTrac and Vigileo are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo and PreSep are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.

© 2006 Edwards Lifesciences LLC
 All rights reserved. AR01907



Edwards Lifesciences